These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model. Habibi M; Asadi Karam MR; Bouzari S Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493 [TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574 [TBL] [Abstract][Full Text] [Related]
17. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target? Eris D; Preston RC; Scharenberg M; Hulliger F; Abgottspon D; Pang L; Jiang X; Schwardt O; Ernst B Chembiochem; 2016 Jun; 17(11):1012-20. PubMed ID: 26991759 [TBL] [Abstract][Full Text] [Related]
18. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists. Scharenberg M; Jiang X; Pang L; Navarra G; Rabbani S; Binder F; Schwardt O; Ernst B ChemMedChem; 2014 Jan; 9(1):78-83. PubMed ID: 24357503 [TBL] [Abstract][Full Text] [Related]
19. Developments in Mannose-Based Treatments for Uropathogenic Escherichia coli-Induced Urinary Tract Infections. Hatton NE; Baumann CG; Fascione MA Chembiochem; 2021 Feb; 22(4):613-629. PubMed ID: 32876368 [TBL] [Abstract][Full Text] [Related]
20. Binding of the Bacterial Adhesin FimH to Its Natural, Multivalent High-Mannose Type Glycan Targets. Sauer MM; Jakob RP; Luber T; Canonica F; Navarra G; Ernst B; Unverzagt C; Maier T; Glockshuber R J Am Chem Soc; 2019 Jan; 141(2):936-944. PubMed ID: 30543411 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]